Abstract
Proteins can be encapsulated in niosomes as they are known to protect proteins against the surrounding env ironment. Niosomes of Span™ 65/cholesterol/pluronic® F -127 were prepared by thin film hydration method. Insulin and lysozyme were chosen as model proteins. Niosomes were chara c-terised for morphology by Transmission Electron M icroscopy (TEM) and vesicles size using Dynamic Light Scattering. The entrapment efficiency of protein in niosomes was determined by complete vesi-cle disruption using 50:50% isopropanol:buf fer, followed by analysis of the resulting so lutions by HPLC method. Thermal behaviour of the niosomes was investigated using Differential Scanning Calo-rimetry (DSC). Protection of proteins against simulated gastric fluid (SGF) and simu lated intestinal fluid (SIF) were also assessed. The results showed that niosomes prepared with diffe r ent molar ratios % of Span™ 65, cholesterol and pluronic®F -127 successfully produced with insulin and lysozyme. For insulin co n taining niosomes, the ratio % of 64.7 (Span™ 65): 32.3 (cholesterol): 3.0 (pluronic® F - 127) produced the highest protein encapsulation eff i-ciency and the smallest vesicle size of 653.6 nm. For lysozyme containing niosomes, the maximum pr o tein encapsulation was found in 72.75/24.25/3.00% molar ratio of Span™ 65/cholesterol/pluronic® F -127 niosomes with vesi cle size of 627.3 nm. The release study of proteins from the niosomal preparations in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) revealed that insulin and lysozyme efflux from the niosomes is a biphasic process. The results indicate that Span™ 65 niosomes could be developed as controlled release dosage forms for delivery of peptides and proteins such as insulin and lysozyme.
Keywords: Niosomes, insulin, lysozyme, SpanTM 65, cholesterol, pluronic® F-127, encapsulation efficiency.
Graphical Abstract
Current Drug Delivery
Title:In vitro characterisation of Span™ 65 niosomal formulations containing proteins
Volume: 12 Issue: 5
Author(s): Rita Rochdy Haj-Ahmad, Amal Ali Elkordy and Cheng Shu Chaw
Affiliation:
Keywords: Niosomes, insulin, lysozyme, SpanTM 65, cholesterol, pluronic® F-127, encapsulation efficiency.
Abstract: Proteins can be encapsulated in niosomes as they are known to protect proteins against the surrounding env ironment. Niosomes of Span™ 65/cholesterol/pluronic® F -127 were prepared by thin film hydration method. Insulin and lysozyme were chosen as model proteins. Niosomes were chara c-terised for morphology by Transmission Electron M icroscopy (TEM) and vesicles size using Dynamic Light Scattering. The entrapment efficiency of protein in niosomes was determined by complete vesi-cle disruption using 50:50% isopropanol:buf fer, followed by analysis of the resulting so lutions by HPLC method. Thermal behaviour of the niosomes was investigated using Differential Scanning Calo-rimetry (DSC). Protection of proteins against simulated gastric fluid (SGF) and simu lated intestinal fluid (SIF) were also assessed. The results showed that niosomes prepared with diffe r ent molar ratios % of Span™ 65, cholesterol and pluronic®F -127 successfully produced with insulin and lysozyme. For insulin co n taining niosomes, the ratio % of 64.7 (Span™ 65): 32.3 (cholesterol): 3.0 (pluronic® F - 127) produced the highest protein encapsulation eff i-ciency and the smallest vesicle size of 653.6 nm. For lysozyme containing niosomes, the maximum pr o tein encapsulation was found in 72.75/24.25/3.00% molar ratio of Span™ 65/cholesterol/pluronic® F -127 niosomes with vesi cle size of 627.3 nm. The release study of proteins from the niosomal preparations in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) revealed that insulin and lysozyme efflux from the niosomes is a biphasic process. The results indicate that Span™ 65 niosomes could be developed as controlled release dosage forms for delivery of peptides and proteins such as insulin and lysozyme.
Export Options
About this article
Cite this article as:
Haj-Ahmad Rochdy Rita, Elkordy Ali Amal and Chaw Shu Cheng, In vitro characterisation of Span™ 65 niosomal formulations containing proteins , Current Drug Delivery 2015; 12 (5) . https://dx.doi.org/10.2174/1567201812666150511095432
DOI https://dx.doi.org/10.2174/1567201812666150511095432 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tumour Re-Differentiation Effect of Retinoic Acid: A Novel Therapeutic Approach for Advanced Thyroid Cancer
Current Pharmaceutical Design Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry The Proportion of Type 2 Diabetic Patients Achieving Treatment Goals and the Survey of Patients’ Attitude Towards Insulin In tiation ini Patient s with Inadequate Glycaemic Control with Oral Anti-diabetic Drugs
Current Diabetes Reviews Cardioprotection with opioids - Trusted old friends -Clinical Science -
Current Pharmaceutical Design Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry Toxic Effects of Aflatoxin B1 on Embryonic Development of Zebrafish (Danio rerio): Potential Activity of Piceatannol Encapsulated Chitosan/poly (Lactic Acid) Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Cysteinyl Leukotrienes (CysLTs): Role in Obesity-Induced Asthma
Current Molecular Medicine Epigenetic Modifications Associated with the Pathogenesis of Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Clinical Significance of the New Cardiovascular Risk Markers in Diabetes Mellitus
Current Diabetes Reviews Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Cardiosphere-derived Progenitor Cells for Myocardial Repair Following Myocardial Infarction
Current Pharmaceutical Design The Lung in Sepsis: Guilty or Innocent?
Endocrine, Metabolic & Immune Disorders - Drug Targets Social Determinants of Childhood Obesity: Beyond Individual Choices
Current Pediatric Reviews Clinical Advances in Bone Regeneration
Current Stem Cell Research & Therapy Neuromyelitis Optica (NMO IgG+) and Genetic Susceptibility, Potential Ethnic Influences
Central Nervous System Agents in Medicinal Chemistry Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Emerging Targets for the Treatment of Dyslipidemia
Current Medicinal Chemistry Recent Advances in Protein and Peptide Drug Delivery Systems
Current Drug Delivery Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets Editorial: MicroRNA: A Small Molecule with a Big Biological Impact
MicroRNA